Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 12/20 | 0.61 |
| ▸ | CA1 | P00915 | 12/20 | 0.61 |
| ▸ | CA2 | P00918 | 12/20 | 0.61 |
| ▸ | CA7 | P43166 | 12/20 | 0.61 |
| ▸ | CA9 | Q16790 | 12/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 12/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.51 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.50 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1136719 | 0.85 | L3MBTL3 (0.59) | CA12CA1CA2CA7CA9 | |
| Bromide SCHEMBL1136932 | 0.84 | L3MBTL3 (0.58) | CA12CA1CA2CA7CA9 | |
| Hydrochloric Acid SCHEMBL1136918 | 0.84 | L3MBTL3 (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL23775472 | 0.81 | CRHBP (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL17277458 | 0.81 | KMT2A (0.69) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2950903 | 0.80 | LMNA (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL13575475 | 0.79 | MGLL (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL23775674 | 0.79 | MGLL (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL15566282 | 0.78 | SIGMAR1 (0.60) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3570536 | 0.78 | CA12 (0.78) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2010-10-14 | — | — | US | disclosed |
| US-7767674-B2 | Kinase inhibitors | ELI LILLY AND COMPANY (US) | 2010-08-03 | — | — | US | disclosed |
| US-7767674-B2 | Kinase inhibitors | ELI LILLY AND COMPANY (US) | 2010-08-03 | — | — | US | disclosed |
| US-7767674-B2 | Kinase inhibitors | ELI LILLY AND COMPANY (US) | 2010-08-03 | — | — | US | disclosed |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-09-17 | — | — | US | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
| US-20080306068-A1 | Suppression cytokines, tumor necrosis factor | ELI LILLY AND COMPANY (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306068-A1 | Suppression cytokines, tumor necrosis factor | ELI LILLY AND COMPANY (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306068-A1 | Suppression cytokines, tumor necrosis factor | ELI LILLY AND COMPANY (US) | 2008-12-11 | — | — | US | disclosed |
| EP-1761520-B1 | KINASE INHIBITORS | LILLY CO ELI (US) | 2008-07-09 | — | — | EP | disclosed |
| EP-1761520-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006009741-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-01-26 | — | — | WO | disclosed |
| EP-1609789-A1 | UREIDO-PYRAZOLE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | CA12 4880/4885CA1 4878/4885CA2 4857/4885 |
| US-20080306068-A1 | Suppression cytokines, tumor necrosis factor | TNF, TNFRSF1A, IL2 | CA12 1571/4885CA1 1153/4885CA2 2028/4885 |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | CA12 4880/4885CA1 4878/4885CA2 4857/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | CA12 4880/4885CA1 4878/4885CA2 4857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.